Previous 10 | Next 10 |
Signed research collaboration with University of California, Irvine, on research program for exosome-based therapies for certain brain disorders Licensee ImStem Biotechnology announced first U.S. multiple sclerosis patient dosed with IMS001 AgeX Therapeutics , In...
AgeX Therapeutics (NYSE:AGE) announces a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles, with the goal of developing therapies to treat adverse neurocognitive effects of cancer chemothera...
Research to explore therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells Research will complement AgeX sponsored program at UCI to develop cell therapies for Huntington’s disease and potent...
ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Pluripotent Stem Cell Line ESI-053 AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, anno...
NYSE American informed AgeX Therapeutics (NYSE:AGE) that it does not meet certain of the Exchange's continued listing standards and that AgeX has stockholders equity of less than $2M and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, ...
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2021. Liquidity and Capital Resources As...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021. Liquidity and Capital Resources As of ...
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ ...
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
News, Short Squeeze, Breakout and More Instantly...
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024 Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024; IND submission to the FDA for the initiation of a Phas...
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended Decembe...
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 211.4% to $0.4422 on volume of 532,901,553 shares Fisker Inc. Class A (FSR) rose 12.8% to $0.1747 on volume of 376,460,729 shares Better Therapeutics Inc. (BTTX) rose 27.4% to $0.0446 on volume...